TY - JOUR
T1 - Myeloma of the central nervous system
T2 - Association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations
AU - Fassas, Athanasios B.T.
AU - Muwalla, Firas
AU - Berryman, Tanya
AU - Benramdane, Riad
AU - Joseph, Lija
AU - Anaissie, Elias
AU - Sethi, Rajesh
AU - Desikan, Raman
AU - Siegel, David
AU - Badros, Ashraf
AU - Toor, Amir
AU - Zangari, Maurizio
AU - Morris, Christopher
AU - Angtuaco, Edgardo
AU - Mathew, Sajini
AU - Wilson, Carla
AU - Hough, Aubrey
AU - Harik, Sami
AU - Barlogie, Bart
AU - Tricot, Guido
PY - 2002
Y1 - 2002
N2 - Involvement of the central nervous system (CNS) by multiple myeloma, as defined by the detection of malignant plasma cells in the cerebrospinal fluid in the presence of suggestive symptoms, is considered extremely rare. We report on the characteristics of 18 such patients diagnosed and treated at the University of Arkansas over the last 10 years for an overall incidence of approximately 1%. Their evaluation revealed association of CNS involvement with unfavourable cytogenetic abnormalities (especially translocations and deletion of the chromosome 13), high tumour mass, plasmablastic morphology, additional extramedullary myeloma manifestations and circulating plasma cells. The presence of these features should alert clinicians to the possibility of CNS involvement. The outcome of these patients was extremely poor despite the use of aggressive local and systemic treatment including autologous stem cell transplants. Given this universally poor prognosis, the application of allogeneic transplants should be studied in this clinical setting.
AB - Involvement of the central nervous system (CNS) by multiple myeloma, as defined by the detection of malignant plasma cells in the cerebrospinal fluid in the presence of suggestive symptoms, is considered extremely rare. We report on the characteristics of 18 such patients diagnosed and treated at the University of Arkansas over the last 10 years for an overall incidence of approximately 1%. Their evaluation revealed association of CNS involvement with unfavourable cytogenetic abnormalities (especially translocations and deletion of the chromosome 13), high tumour mass, plasmablastic morphology, additional extramedullary myeloma manifestations and circulating plasma cells. The presence of these features should alert clinicians to the possibility of CNS involvement. The outcome of these patients was extremely poor despite the use of aggressive local and systemic treatment including autologous stem cell transplants. Given this universally poor prognosis, the application of allogeneic transplants should be studied in this clinical setting.
KW - Allogeneic stem cell transplant
KW - Central nervous system
KW - High-risk features
KW - Multiple myeloma
UR - http://www.scopus.com/inward/record.url?scp=0036223725&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2141.2002.03401.x
DO - 10.1046/j.1365-2141.2002.03401.x
M3 - Article
C2 - 11918539
AN - SCOPUS:0036223725
SN - 0007-1048
VL - 117
SP - 103
EP - 108
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 1
ER -